Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2005-005329-68Phase 2Completed
Phase 2, randomised, double-blind trial of milveterol in asthma (4 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in clinic visit trough FEV1 after 14 days repeat dosing. Started Feb 2006; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2005-005329-68.